Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real Life Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer in the Middle Eastern Countries (REALME)

NCT01320501 is registered in ClinicalTrials.gov with National Guard Health Affairs as lead sponsor.

NCT NCT01320501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01320501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real Life Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer in the Middle Eastern Countries (REALME)
Lead sponsor
National Guard Health Affairs
Phase
Phase 4
Overall status
Suspended
Start date
October 31, 2009
Completion date
August 31, 2016
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer metastatic